Concepedia

Author

Pierre Feugier

Centre Hospitalier Régional et Universitaire de Nancy

Also Known As

C Thieblemont, Feugier, P., Feugier, Pierre, Laure LeBras, P Feugier, P. Feugier, Pierre Feugier

184

Publications

10.9K

Citations

45

H-Index

64

Concepts

All Affiliations

Centre Hospitalier Régional et Universitaire de NancyHôpital Saint-LouisHospices Civils de LyonAssistance Publique – Hôpitaux de ParisInserm
PF

About

Pierre Feugier is an author at Centre Hospitalier Régional et Universitaire de Nancy specializing in medicine, oncology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

19

27

2.9K

2

Health Sciences

8

9

518

3

Public Health

1

1

10

4

Biostatistics

1

1

217

5

Epidemiology

1

1

10

Pierre Feugier

×

89

Publications

10.6K

Citations

45

H-Index

YearCitations

Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

Pierre Feugier, Ambro van Hoof, Catherine Sebban,

Journal of Clinical Oncology

2005

1.5K

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles Salles, John F. Seymour, Fritz Offner,

The Lancet

2010

1.1K

Treatment of Older Patients with Mantle-Cell Lymphoma

Hanneke C. Kluin‐Nelemans, Eva Hoster, Olivier Hermine,

New England Journal of Medicine

2012

511

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

Steven Le Gouill, Catherine Thiéblemont, Lucie Obéric,

New England Journal of Medicine

2017

398

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Olivier Hermine, Eva Hoster, Jan Walewski,

The Lancet

2016

390

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Laëtitia Vercellino, Roberta Di Blasi, Salim Kanoun,

Blood Advances

2020

387

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Franck Morschhauser, Nathan Fowler, Pierre Feugier,

New England Journal of Medicine

2018

357

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

Gilles Salles, Nicolas Mounier, Sophie de Guibert,

Blood

2008

330

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Emmanuel Bachy, John F. Seymour, Pierre Feugier,

Journal of Clinical Oncology

2019

266

Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome

Bruno Chetaille, François Bertucci, Pascal Finetti,

Blood

2008

250

Page 1